Drug Trial Radar · NCT04572295
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Oct 9, 2020
Primary completion
Jun 18, 2026
Study completion Jun 18, 2026
Sponsor
- Lead sponsor
- Eisai Co., Ltd.Eisai
- Sponsor type
- Industry
- First posted
- Oct 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to determine the recommended dose (RD) of E7090 in combination with other anticancer agents for subsequent phase studies.
Conditions
- Breast Neoplasms
Interventions
E7090Drug
E7090 oral tablet.
FulvestrantDrug
Fulvestrant intramuscular injection.
ExemestaneDrug
Exemestane oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Recommended Dose (RD) of E7090 in Combination With Other Anticancer AgentsTime frame: Up to Cycle 1 (each cycle length = 28 days)
- Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Up to Cycle 1 (each cycle length = 28 days)
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 30 days after last administration of study drug (approximately up to 66 months)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Eisai Trial Site 11
Nagoya, Aichi-ken, Japan
Eisai Trial Site 6
Kashiwa, Chiba, Japan
Eisai Trial Site 9
Matsuyama, Ehime, Japan
Eisai Trial Site 5
Yokohama, Kanagawa, Japan
Eisai Trial Site 4
Sendai, Miyagi, Japan
Eisai Trial Site 7
Chuo-ku, Osaka, Japan
Eisai Trial Site 10
Kitaadachi-gun, Saitama, Japan
Eisai Trial Site 3
Chuo-ku, Tokyo, Japan
Eisai Trial Site 1
Koto-ku, Tokyo, Japan
Eisai Trial Site 2
Shinagawa-ku, Tokyo, Japan
Eisai Trial Site 8
Shinjuku-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.